Form 4: KALA BIO Director Howard Rosen Granted Equity Awards, Boosting Stake

KALA BIO, Inc. Director Howard B. Rosen was granted 2,450 restricted stock units and 5,450 stock options, increasing his beneficial ownership in the company.

Summary

• Howard B. Rosen, a Director of KALA BIO, Inc. (KALA), was granted equity awards on June 15, 2025.
• He received 2,450 Restricted Stock Units (RSUs) at a price of $0 per unit, representing a contingent right to receive one share of common stock each.
• He also received 5,450 stock options with an exercise price of $4.3 per share.
• Both the RSUs and stock options will vest 100% on the earlier of June 15, 2026, or the date of the first annual meeting of stockholders occurring in 2026, contingent on his continued service.
• Following these transactions, Mr. Rosen directly beneficially owns 16,240 shares of common stock, which includes 7,776 unvested RSUs.
• Additionally, he indirectly owns 262 shares through the Rosen/Doherty Revocable Trust Dated 6/11/01.
• He also directly beneficially owns 5,450 stock options.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it represents a standard equity grant to a director, aligning their interests with shareholders. While it implies future dilution, it's a common and expected form of compensation.

Positives

• The grant of RSUs and stock options to Director Howard B. Rosen aligns his interests with those of shareholders, as his compensation is tied to the company's future performance.
• The increase in direct beneficial ownership by a director can signal confidence in the company's long-term prospects.

Negatives

• The issuance of new equity awards, while standard for compensation, can lead to potential future dilution if the options are exercised and RSUs vest, increasing the total number of outstanding shares.

Future Outlook

NA

Industry Context

This Form 4 filing details a standard equity compensation grant to a director, a common practice across industries to incentivize long-term performance and align management interests with shareholder value. It does not provide broader industry trends or competitive analysis.

Related Party Transactions

• The grant of 2,450 Restricted Stock Units and 5,450 stock options to Howard B. Rosen, a Director of KALA BIO, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: Potential future dilution from the vesting and exercise of equity awards, but also increased alignment of director's interests with shareholder value.
• Employees: No direct impact mentioned, but reflects standard compensation practices for leadership.

Next Steps

• The granted Restricted Stock Units (RSUs) and stock options are scheduled to vest on the earlier of June 15, 2026, or the date of the first annual meeting of stockholders occurring in 2026.

Key Dates

Keywords

KALA BIO, KALA, Howard B. Rosen, SEC Form 4, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Director Compensation, Beneficial Ownership